Home / Stocks / NVO

Novo Nordisk A/S (NVO, Drugmakers) Stock Valuation & Fair Value Mixed on our tests

Novo Nordisk A/S (NVO, Drugmakers) trades at a current P/E of 11.3, about 53% below its historical normal valuation, with a forward growth estimate of 2.5% and a PEG of 4.47. Analysts' one-year estimates have been hit 82% of the time. Priced at its historical normal P/E of 24.1 on the same blended earnings, the 2026-10-09 close of $38.64 corresponds to about $82.50 a share. This is a valuation reference, not a price target.

No quality score is published for this company, which is normal for insurers, banks and REITs. This rating reflects valuation and forecast return, and for the top ratings, credit rating, growth and analyst accuracy.

DATA AS OF 2026-10-12
Current P/E
11.3
Normal P/E
24.1
PEG
4.47
Fwd growth
2.5%
Div yield
3.3%
RSI (14)
37.7
Neutral
Technical context
  • Price $38.58 at the 2026-10-12 close, 1.6% below the 20-day average ($39.19) and 10.6% below the 50-day ($43.14).
  • RSI (14) at 37.7.
  • 52-week range $34.33 to $60.94: the price is 36.7% below the high and 12.4% above the low.

The Street vs SeerForecast

Wall Street's mean price target for NVO is $46.12 across 12 analysts, 19.5% above the current price. The average analyst rating is Hold. Our SeerForecast read of the same stock, formed without analyst targets: mixed on our tests. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been mixed on our tests since 2026-06-14.

Current P/E and rating by weekCurrent P/E moved from 12.5 to 11.3 between 2026-06-12 and 2026-10-09, against a normal P/E of 24.1, with 3 rating changes over 34 recorded weeks.2026-06-12: P/E 12.5, Mixed on our tests, recalculated for the week of 2026-06-142026-06-16: P/E 12.5, Mixed on our tests, recalculated for the week of 2026-06-162026-06-18: P/E 12.5, Mixed on our tests, recalculated for the week of 2026-06-212026-07-02: P/E 12.5, Mixed on our tests, recalculated for the week of 2026-07-022026-07-06: P/E 12.5, Mixed on our tests, recalculated for the week of 2026-07-062026-07-09: P/E 12.5, Mixed on our tests, recalculated for the week of 2026-07-092026-07-10: P/E 12.5, Mixed on our tests, recalculated for the week of 2026-07-122026-07-13: P/E 12.5, Mixed on our tests, recalculated for the week of 2026-07-132026-07-14: P/E 12.5, Mixed on our tests, recalculated for the week of 2026-07-142026-07-20: P/E 12.5, Mixed on our tests, recalculated for the week of 2026-07-202026-07-31: P/E 15.0, Poor on forward returns, recalculated for the week of 2026-07-312026-07-31: P/E 13.7, Weak on forward returns, recorded live 2026-08-032026-08-07: P/E 13.7, Weak on forward returns, recalculated for the week of 2026-08-072026-08-07: P/E 13.7, Weak on forward returns, recorded live 2026-08-102026-08-14: P/E 13.7, Weak on forward returns, recalculated for the week of 2026-08-142026-08-14: P/E 13.1, Weak on forward returns, recorded live 2026-08-172026-08-21: P/E 13.1, Weak on forward returns, recalculated for the week of 2026-08-212026-08-21: P/E 13.4, Weak on forward returns, recorded live 2026-08-242026-08-27: P/E 13.4, Weak on forward returns, recalculated for the week of 2026-08-272026-08-28: P/E 13.4, Weak on forward returns, recalculated for the week of 2026-08-282026-08-28: P/E 13.4, Weak on forward returns, recalculated for the week of 2026-08-302026-08-28: P/E 13.0, Mixed on our tests, recorded live 2026-08-312026-09-04: P/E 13.0, Mixed on our tests, recalculated for the week of 2026-09-052026-09-04: P/E 13.3, Mixed on our tests, recorded live 2026-09-072026-09-11: P/E 13.3, Mixed on our tests, recalculated for the week of 2026-09-122026-09-11: P/E 12.3, Mixed on our tests, recorded live 2026-09-142026-09-18: P/E 12.3, Mixed on our tests, recalculated for the week of 2026-09-192026-09-18: P/E 12.4, Mixed on our tests, recorded live 2026-09-212026-09-25: P/E 11.2, Mixed on our tests, recalculated for the week of 2026-09-262026-09-25: P/E 11.2, Mixed on our tests, recorded live 2026-09-282026-10-02: P/E 10.8, Mixed on our tests, recalculated for the week of 2026-10-032026-10-02: P/E 10.8, Mixed on our tests, recorded live 2026-10-052026-10-09: P/E 11.3, Mixed on our tests, recalculated for the week of 2026-10-102026-10-09: P/E 11.3, Mixed on our tests, recorded live 2026-10-1215.020.0Jun 12Jul 12Aug 11Sep 9Oct 9Normal P/E 24.1
Mixed on our testsWeak on forward returnsPoor on forward returnsLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekCurrent P/EPremium to normal P/ERating
2026-06-14P/E 12.5-48%Mixed on our tests (recalculated)
2026-07-31P/E 15.0-38%Poor on forward returns (recalculated)
2026-08-03P/E 13.7-43%Weak on forward returns
2026-08-31P/E 13.0-46%Mixed on our tests
2026-10-03P/E 10.8-55%Mixed on our tests (recalculated)
2026-10-12P/E 11.3-53%Mixed on our tests ← now
Show all 34 weeks
WeekCurrent P/EPremium to normal P/ERating
2026-06-14P/E 12.5-48%Mixed on our tests (recalculated)
2026-06-16P/E 12.5-48%Mixed on our tests (recalculated)
2026-06-21P/E 12.5-48%Mixed on our tests (recalculated)
2026-07-02P/E 12.5-48%Mixed on our tests (recalculated)
2026-07-06P/E 12.5-48%Mixed on our tests (recalculated)
2026-07-09P/E 12.5-48%Mixed on our tests (recalculated)
2026-07-12P/E 12.5-48%Mixed on our tests (recalculated)
2026-07-13P/E 12.5-48%Mixed on our tests (recalculated)
2026-07-14P/E 12.5-48%Mixed on our tests (recalculated)
2026-07-20P/E 12.5-48%Mixed on our tests (recalculated)
2026-07-31P/E 15.0-38%Poor on forward returns (recalculated)
2026-08-03P/E 13.7-43%Weak on forward returns
2026-08-07P/E 13.7-43%Weak on forward returns (recalculated)
2026-08-10P/E 13.7-43%Weak on forward returns
2026-08-14P/E 13.7-43%Weak on forward returns (recalculated)
2026-08-17P/E 13.1-45%Weak on forward returns
2026-08-21P/E 13.1-45%Weak on forward returns (recalculated)
2026-08-24P/E 13.4-44%Weak on forward returns
2026-08-27P/E 13.4-44%Weak on forward returns (recalculated)
2026-08-28P/E 13.4-44%Weak on forward returns (recalculated)
2026-08-30P/E 13.4-44%Weak on forward returns (recalculated)
2026-08-31P/E 13.0-46%Mixed on our tests
2026-09-05P/E 13.0-46%Mixed on our tests (recalculated)
2026-09-07P/E 13.3-45%Mixed on our tests
2026-09-12P/E 13.3-45%Mixed on our tests (recalculated)
2026-09-14P/E 12.3-49%Mixed on our tests
2026-09-19P/E 12.3-49%Mixed on our tests (recalculated)
2026-09-21P/E 12.4-48%Mixed on our tests
2026-09-26P/E 11.2-54%Mixed on our tests (recalculated)
2026-09-28P/E 11.2-54%Mixed on our tests
2026-10-03P/E 10.8-55%Mixed on our tests (recalculated)
2026-10-05P/E 10.8-55%Mixed on our tests
2026-10-10P/E 11.3-53%Mixed on our tests (recalculated)
2026-10-12P/E 11.3-53%Mixed on our tests ← now

Frequently asked questions

Is Novo Nordisk A/S stock overvalued?

At a current P/E of 11.3 versus its historical normal P/E of 24.1, Novo Nordisk A/S trades about 53% below its typical valuation, with a PEG of 4.47 on 2.5% forward growth. tickerseer currently rates it mixed on our tests.

What is Novo Nordisk A/S's fair value and PEG?

Novo Nordisk A/S trades at a current P/E of 11.3 against a historical normal P/E of 24.1, a PEG of 4.47, and a forward growth estimate of 2.5%. Priced at its historical normal P/E of 24.1 on the same blended earnings, the 2026-10-09 close of $38.64 corresponds to about $82.50 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Novo Nordisk A/S changed?

tickerseer's rating has been mixed on our tests since 2026-06-14.

What is the analyst price target for Novo Nordisk A/S?

The mean Wall Street price target for Novo Nordisk A/S is $46.12 across 12 analysts, 19.5% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Drugmakers. Create a free account to see the full analysis: the SeerAI score, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track NVO free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.